Lipid nanoparticle encapsulated TLR3 agonist adjuvant elicits potent T cell immunity against cancer and viruses.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Lipid nanoparticle encapsulated TLR3 agonist adjuvant elicits potent T cell immunity against cancer and viruses.
- Published In:
- NPJ vaccines, 11(1), 26 (2025)
- Authors:
- Ko, Kwang Hyun, Lee, Seung-Hwan, Choi, Young-Ho, Kang, Soon Myung, Yang, Hyun-Suk, Lee, So Min, Jo, Eun Bi, Bae, Hyun Shik, Hong, Seung-Beom, Kim, Dong-Ho, Cha, Seung Bin
- Database ID:
- RPEP-11875
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-11875APA
Ko, Kwang Hyun; Lee, Seung-Hwan; Choi, Young-Ho; Kang, Soon Myung; Yang, Hyun-Suk; Lee, So Min; Jo, Eun Bi; Bae, Hyun Shik; Hong, Seung-Beom; Kim, Dong-Ho; Cha, Seung Bin. (2025). Lipid nanoparticle encapsulated TLR3 agonist adjuvant elicits potent T cell immunity against cancer and viruses.. NPJ vaccines, 11(1), 26. https://doi.org/10.1038/s41541-025-01349-w
MLA
Ko, Kwang Hyun, et al. "Lipid nanoparticle encapsulated TLR3 agonist adjuvant elicits potent T cell immunity against cancer and viruses.." NPJ vaccines, 2025. https://doi.org/10.1038/s41541-025-01349-w
RethinkPeptides
RethinkPeptides Research Database. "Lipid nanoparticle encapsulated TLR3 agonist adjuvant elicit..." RPEP-11875. Retrieved from https://rethinkpeptides.com/research/ko-2025-lipid-nanoparticle-encapsulated-tlr3
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.